Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.

about

Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.

Item

http://www.wikidata.org/entity/Q49954597

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Emerging first line treatment ...... III therapies in the pipeline.

@en

Emerging first line treatment ...... III therapies in the pipeline.

@nl

type

Item

label

Emerging first line treatment ...... III therapies in the pipeline.

@en

Emerging first line treatment ...... III therapies in the pipeline.

@nl

prefLabel

Emerging first line treatment ...... III therapies in the pipeline.

@en

Emerging first line treatment ...... III therapies in the pipeline.

@nl

P1476

Emerging first line treatment ...... III therapies in the pipeline.

@en

P2093

Guru Sonpavde

http://www.w3.org/2001/XMLSchema#string

Omer Jamy

http://www.w3.org/2001/XMLSchema#string

P2860

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Immune checkpoint blockade: a common denominator approach to cancer therapy

The future of immune checkpoint therapy

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Mutational landscape and significance across 12 major cancer types

Comprehensive molecular characterization of urothelial bladder carcinoma

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

P304

347-355

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/14728214.2017.1416092

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29226734

http://www.w3.org/2001/XMLSchema#string